Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $4 (cash outflow) fell 100.0% year over year, behind the -55.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at -33.4% a year.
Context
- Capital expenditures amounted to 437.2% of revenue in FY2025, up 213.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -55.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (285.7K) USD
- Year-over-year change
- +41.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (285.7K) | +41.4% |
| FY2024 | 2024-12-31 | (487.83K) | -52.0% |
| FY2023 | 2023-12-31 | (320.9K) | +66.9% |
| FY2022 | 2022-12-31 | (969.15K) | +21.3% |
| FY2021 | 2021-12-31 | (1.23M) | — |
Capital Expenditures vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 capital expenditures of $226.33K is the 3rd largest of the 10 companies compared; the peer median is $9K.
- Its year-over-year change of -55.8% is the 3rd highest of 8, against a peer median of -81.3%.
- Over three fiscal years its annual growth of -33.4% compares with a peer median of -57.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5M | +171.5% | -44.9% | 79.1% | |
| LTM Mar 2026 | $1.41M | -59.4% | -44.1% | 9.4% | |
| LTM Mar 2026 | $226.33K | -55.8% | -33.4% | — | |
| LTM Mar 2026 | $218K | -38.1% | -70.5% | 19.0% | |
| LTM Mar 2026 | $139K | -81.3% | -78.5% | 0.8% | |
| LTM Mar 2026 | $9K | -89.3% | -18.2% | — | |
| LTM Mar 2026 | $1K | -99.8% | -77.9% | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6 | -220.0% | — | — |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INO) | $9K | -81.3% | -57.7% | 0.8% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| Deferred Income Tax | 0 | 4.03M | (32.05K) | 0 | 0 |
| Stock-Based Compensation | 26.34M | 22.56M | 11.07M | 6.6M | 3.76M |
| Change in Working Capital | 50.35M | 19.83M | (10.26M) | (2.66M) | (9.22M) |
| Accounts Receivables | 11.03M | (3.71M) | 9.33M | 1.21M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 26.14M | 32.61M | (45.99M) | (3.37M) | (6.42M) |
| Other Working Capital | 13.18M | (9.07M) | 26.4M | (504.04K) | (2.8M) |
| Other Non-Cash Items | 6.53M | 11.69M | 6.47M | (3.88M) | (1.21M) |
| Operating Cash Flow | (215.71M) | (216.22M) | (124.37M) | (104.08M) | (88.63M) |
| Capital Expenditures | (1.23M) | (969.15K) | (320.9K) | (487.83K) | (285.7K) |
| Acquisitions (Net) | 0 | (2M) | 6.22M | 0 | 0 |
| Purchases of Investments | (348.95M) | (248.53M) | (203.48M) | (54.14M) | (4.95M) |
| Sales of Investments | 174.84M | 361.08M | 284.93M | 158.64M | 19.27M |
| Other Investing Activities | 0 | 0 | 0 | 59.32K | 0 |
| Investing Cash Flow | (175.34M) | 109.59M | 87.36M | 104.07M | 14.04M |
| Debt Repayment | 0 | 0 | 0 | (16.42M) | 0 |
| Common Stock Issued | 209.44M | 82.96M | 5.46M | 68.31M | 53.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.06M | (1.11M) | (466.65K) | (420.8K) | (110.78K) |
| Financing Cash Flow | 211.5M | 81.84M | 5M | 51.48M | 53.05M |
| Effect of Forex Changes | (30.13K) | (25.56K) | (3.92K) | 32.4K | 0 |
| Net Change in Cash | (179.58M) | (24.81M) | (32.02M) | 51.5M | (21.54M) |
| Free Cash Flow | (216.94M) | (217.18M) | (124.69M) | (104.56M) | (88.92M) |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.